Vitamin K Antagonists and Risk of Subdural Hematoma: Meta-Analysis of Randomized Clinical Trials [Clinical Sciences]
Conclusions—
VKA use significantly increases the risk of subdural hematoma by 3-fold relative to antiplatelet therapy. Direct-acting oral anticoagulants are associated with a significantly reduced risk of subdural hematomas versus VKAs. Based on indirect comparisons to VKAs, the risks of subdural hematoma are similar with antiplatelet monotherapies and factor Xa inhibitors.
Source: Stroke - Category: Neurology Authors: Connolly, B. J., Pearce, L. A., Hart, R. G. Tags: Coumarins Clinical Sciences Source Type: research
More News: Atrial Fibrillation | Bleeding | Clinical Trials | Neurology | Stroke | Vitamin K | Vitamins